CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
This guide reviews criteria to determine the best cheap dividend ETF, including cost structure, track record, and diversification benefits for investors.
22,535 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A U.S. regulator just opened a door for an ambitious ocean mining player. This article breaks down what the NOAA appr...
Small-cap biotech Aethlon Medical faces a pivotal year in 2026. This guide breaks down what to watch in aethlon (aemd...
SailPoint faced a sharp pullback after its latest results, sparking questions about growth and profitability. This ar...
Alphabet raising $84.75 billion marks a bold turn in how tech giants fund AI bets. This article breaks down what it c...
A convincing fake bank call sent a Virginia resident on a cash handoff, revealing how scammers use authority and urge...
Retirees eyeing Mexico’s Pacific coast weigh a $2,500-a-month budget. This report breaks down costs, healthcare optio...
A casual NYC walk can ignite dating chatter that reaches far beyond tabloids. This article breaks down the financial ...
Illinois has floated a plan to fix its long-broken alcohol tax system. This article explains what the proposal actual...
When a public tribute shines a light on mentors and fathers, it offers more than sentiment—it's a blueprint for famil...
Two Kansas City friends chased upgraded FIFA Fan Festival passes, only to be scammed for $600. This story breaks down...
HomeServices of America and Douglas Elliman scored legal wins this week as they push forward with nationwide homebuye...